Protecting Cash Flow Through Licensing Terms is Critical for Biotech Success

Oxford, UK, March 19th, 2012

The pharmaceutical and biotechnology industry is undergoing considerable change as the patent cliff looms, fostering invention and change, and a strong need for successful partnering. There are also new opportunities to develop in emerging and emerged new markets. What impact are these changes having on companies as they seek partners, to strike the best deal? How can companies be sure that the deal terms they achieve, and associated royalties, are the best possible? The terms of licensing deals are turning back in favour of cash-rich pharmaceutical companies, and there are key lessons to be learned by any aspiring dealmaker.

Deal-making declines by 18% in a year as pharmaceutical companies tighten their belt

Oxford, UK,  January 25th,  2012

Overall pharmaceutical deal-making activity fell by 18% in 2011 as pharmaceutical companies cut R&D expenditure and streamlined their research and development activities, according to research conducted by the UK advisory firm PharmaVentures.

PharmaVentures’ client Sanofi wins Scrip ‘Outsourcing Deal of the Year Award’

Oxford, UK 12 January 2012 - PharmaVentures announced today that it was delighted to play an advisory role in the Sanofi – Covance deal which won Scrip’s ‘Outsourcing Deal of the Year 2011’.

Pfizer, Sanofi and Genentech feature prominently in the Oncology edition of PharmaDeals’ new publication series; Essential Deal Trends

Oxford, UK, October 20th, 2011 - PharmaVentures today announced the launch of PharmaDeals® Essential Deal Trends: Oncology 2011. This new series of reports is essential reading for everyone involved in developing and commercialising new drugs. The first report in the series focuses on oncology.

Pfizer Overtakes GSK but Trails Roche in PharmaDeals’ Corp-METRx Analysis of Deal Activity

Oxford, UK 26 September 2011 - PharmaVentures, the experts in deals and alliances, announced today that Corp-METRx, the new definitive analysis on the dealmaking and financial performance of the top 12 pharmaceutical companies, is launched.

PharmaVentures engaged by Astex Pharmaceuticals to Assist in the divestment of US facility

Oxford, UK 09 September 2011 - PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by leading drug discovery company, Astex Pharmaceuticals to seek a buyer for an established full service CMC (chemistry, manufacturing & controls) & Formulation Facility in Pleasanton, California. The engagement will utilise PharmaVentures' asset divestment expertise in the life sciences sector.

PharmaVentures engaged by Avexa to Assist in the Out-licensing of Apricitabine

Oxford, UK 12 July 2011 - PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection. The engagement will utilise PharmaVentures' global transactional expertise in the healthcare and investment business sectors.

PharmaVentures Divesting More Facilities for Major Pharma Companies

Oxford UK, 28 June 2011: PharmaVentures, experts in deals and alliances, are pleased to announce that they have recently been engaged by two major pharmaceutical companies to divest three facilities in three continents.

New Industry Dynamics to Help Secure the Right Deal

Oxford, UK- June 27 2011 - PharmaDeals®, the publishing division of PharmaVentures, announced today the launch of PharmaDeals v4 Enterprise Edition, a new integrated resource with a comprehensive, searchable and interactive library of reports, articles, agreements, video, graphs and deal data. As well as access to new online content, the resource also provides users with a range of applications and tools for tracking, alerting and analysing information.

PharmaVentures Corporate Advisory appoints Ping Shek as Senior Director in Transactions

PharmaVentures today announced the appointment of Ping Shek as Senior Director in the Transactions division of Corporate Advisory working on a number of key M&A and divestment mandates in the healthcare business sector.

Pages

 

_

PharmaVentures InSights